SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial is the dominant focus, with traders awaiting confirmation of the 80th death that triggers final analysis; the last disclosed count was 78, and speculation links the prolonged wait and company silence to possible ASH disclosures. Bulls interpret the delay as a potential sign of longer survival, while bears question the trial timeline and warn that the outcome remains uncertain; the debate accompanies a sharp share-price decline.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances ESMO data are driving discussion, particularly mature frontline melanoma results for lifileucel plus pembrolizumab showing durable responses and a median progression-free survival of 19.8 months, alongside preliminary sarcoma results. Many traders view the data as supportive of expansion potential, while others stress the small study sizes and say the abstracts largely confirm earlier findings; some attribute the share-price weakness to broader biotech selling rather than a company-specific setback.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is being swept into a sharp selloff across AI neocloud and data-center stocks as investors reassess the sectors debt-funded growth, financing costs, and ability to earn returns on heavy infrastructure spending. Traders are split between viewing the decline as an oversold, sector-wide repricing and warning that debt and profitability risks could drive further losses.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp futures rebound after a bruising week, ahead of major tech earnings, has put SPY in focus amid chatter about the 1987 Black Monday anniversary. Traders are split on whether the move signals a durable recovery or a short-covering bounce that could fade at the open.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp futures rebound after a bruising tech selloff is driving QQQ discussion, alongside fears tied to the Black Monday anniversary. Traders are split on whether the bounce marks a durable recovery ahead of major tech earnings or a short-covering rally that could fade, with AI-sector concerns still weighing on sentiment.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Concern over IPO lockup expirations and the potential for insider-share selling is a recurring focus as CBRS faces a steep decline. Traders also point to weakness across AI and semiconductor stocks and question the companys high valuation, growth prospects, and reliance on OpenAI; others argue the selloff is overdone and are buying the dip.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerrys QNX growth storyparticularly a major Alloy Kore vehicle-platform design win and an Uber design win, alongside stronger results and a raised outlookis driving discussion. Bullish traders see potential in software-defined vehicles and physical AI, while skeptics question how quickly design wins will translate into revenue and note the share-price weakness.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

XBI is drawing attention amid a broad biotech selloff that traders link to rising yields, rate concerns, and rotation away from riskier small-cap names toward AI and other sectors. The community is split between viewing the decline as an oversold buying opportunity and warning that technical weakness and macro pressure could drive further losses.

GEOM maps the world's oil fields, mines, rare earths, and power plants, tracks what is and isn't tokenized, and cryptographically signs every dataset it publishes. Anyone can verify what we said and when. No account, no key, no permission. Sources include the WRI Global Power Plant Database and Global Energy Monitor (CC BY 4.0), attributed in full inside the app. Most of it already exists, spread across filings and terminals no one reads. GEOM gathers it and records where each figure came from.

GEOM

Attention centers on the proposed GEOM platform for tokenizing energy and mineral assets and royalties, which traders link to Greenland Energy and USFM; bullish holders are anticipating a platform demo, launch, or partner announcement. Others question the tokens verified utility and connections, citing thin liquidity, sharp swings, and rug-pull risk.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is drawing attention amid a pullback alongside broader crypto weakness, with traders citing Bitcoins softness and leveraged liquidations. The community is split between buying and staking the dip and expecting further downside; technical posts describe consolidation near support.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?

Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

These Two Healthcare Stocks Hit Key Milestones Today – Why Is Wall Street Bullish On Them?

Equity

Orchestra BioMed received an upgrade from BTIG while LifeStance Health Group received a price target hike from Barclays.

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -8.57% and -32.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Orchestra BioMed Holdings, Inc. Q2 Sales Decline

(RTTNews) - Orchestra BioMed Holdings, Inc. (OBIO) announced Loss for second quarter of -$24.079 million...

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +16.98% and -94.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +0.94% and +18.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +1.12% and -57.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Orchestra BioMed (OBIO) to Release Quarterly Earnings on Monday

Orchestra BioMed (NASDAQ:OBIO) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-orchestra-biomed-holdings-inc-stock...

NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of -55.00% and +3.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Sees Large Growth in Short Interest

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling...

This account has been verified as an official OBIO representative.

Verified Account

Orchestra BioMed

Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company was founded by David P. Hochman on May 25, 2020 and is headquartered in New Hope, PA.

Orchestra BioMed Holdings Inc

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$5.45
Prev Close	$5.74
Open	$5.75
Dividend Yield	0.00%
50-Day Moving Average	$5.50
Beta	1.71
Avg. Volume	367,833.46
PE Ratio	-5.45

52-Week High	$6.50
52-Week Low	$3.34
Market Capitalization	$327.57M
EPS (Annual)	-$1.11
Price to Book	16.95
Revenue Per Employee	$389,325.58

Feed

News

Sentiment

Earnings

Fundamentals

Info

OBIO Fundamentals